Orchid Pharma Limited (ORCHPHARMA) Earnings Call Transcripts

Orchid Pharma Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Orchid Pharma Limited reported stand-alone revenue of approximately INR 238 crores, marginally up from INR 237 crores in Q4 FY '25, indicating stabilization after a challenging year for the antibiotic sector. The company's EBITDA improved to INR 42.3 crores from INR 40 crores year-over-year, although full-year revenue declined to INR 811 crores from INR 922 crores in FY '25, with EBITDA decreasing from INR 155 crores to INR 101 crores. Management signaled cautious optimism regarding recovery in the pricing cycle and operational efficiencies, while maintaining a target of 10-15% growth for FY '27.

Reported metrics

Guidance from management

Management targets a revenue growth of 10-15% for FY '27, indicating a return to growth after a challenging FY '26. They remain cautious about the pricing environment but believe the worst may be behind them.

What management said

Yes, sure. Thanks for your question. So specifically country-wise comments, I won't be able to share because of confidentiality in the way our agreements are structured. Like Mr. Manish explained in his speech, in some countries, we have reached a term sheet stage, and we are negotiating the definitive agreements. So depending on where they are, these long-term agreements are taking more time to negotiate than we tho...

So just adding on to that, some of the key opinion leaders now that we are talking to various countries in various markets. So everywhere we are getting a feedback that this is a very important product with respect to launch and every country would like to have it. The only question remains of the economics of how it's going to be priced. But with respect to the attractiveness of the product, so every country we appr...

What analysts pressed on

Analysts expressed concerns about the sustainability of pricing improvements and the potential impact of geopolitical factors on costs. There were also questions regarding the timeline for out-licensing agreements for Enmetazobactam and the overall market dynamics affecting Orchid's growth prospects.

Main topics on the call

• Revenue Stabilization — Orchid reported Q4 FY '26 revenue of INR 238 crores, stable year-over-year, signaling a return to normalcy after previous declines. Management stated, "We believe this signals a back to business as usual compared to very...
• EBITDA Improvement — The company's EBITDA for Q4 FY '26 increased to INR 42.3 crores, up from INR 40 crores in the same quarter last year. This improvement reflects effective cost management despite ongoing industry challenges.
• Merger with Dhanuka Laboratories — The merger is expected to enhance operational efficiencies and could contribute an estimated 1-2% EBITDA margin expansion. Management emphasized that the merger creates a unified anti-infective platform, stating, "The me...
• 7ACA Project Progress — The 7ACA project remains on track for commissioning in Q1 CY '27, with management expressing confidence in its strategic importance. They noted, "We are still committed to the commissioning in the first quarter of calend...

Read the full Orchid Pharma Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 7 Orchid Pharma Limited earnings call transcripts on record, spanning February 9, 2024 to May 26, 2026. Based on this history, Orchid Pharma Limited reports semi-annually. The most recent call on file is dated May 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ORCHPHARMA

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

7

First call

February 9, 2024

Most recent

May 26, 2026

Reporting cadence

semi-annually